Catalent jumps into ADCs with Redwood deal

As more and more drugmakers eye antibody-drug conjugate development as a path to blockbusters, Catalent has licensed ADC technology from Redwood Bioscience, planning to roll the offering into its service platform.

Under the deal, Catalent gets exclusive rights to sub-license Redwood's technology, called SMARTag, and the CRO will take a minority stake in Redwood with the option to buy it in the future.

The technology combines the binding benefits of monoclonal antibodies with the potency of small-molecule chemotherapy treatments, Catalent said, allowing developers to more accurately and effectively deliver toxic therapies. And, with Roche's ($RHHBY) recent FDA victory with the ADC-powered Kadcyla, the technology is an in-demand component of biologic anti-cancer treatment, Catalent said.

"We believe that Redwood is an industry leader in site-specific conjugation," Catalent Medication Delivery Solutions President Barry Littlejohns said in a statement. "Their innovative technologies will provide significant value to our customers looking to develop next-generation ADC therapies."

The newly licensed Redwood technology dovetails with Catalent's recent investments in biomanufacturing, the company said, including its new state-of-the-art facility in Wisconsin.

Catalent has already had a busy 2013, investing to its expand its presence around the world and in various therapeutic areas. In January, the company poured about $20 million into North Carolina-based inhalant unit, and last month it launched two Chinese joint ventures, teaming up with local companies for softgel manufacturing and clinical trial supply.

- read Catalent's statement

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.